/
Other
Immune Response
25
Pipeline Programs↗
25
Active Trials↗
19
Companies Involved↗
Immune Response is an emerging landscape with 25 programs across 19 companies. The most active players are GSK, BioNTech. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 12
Phase 24
Phase 36
Approved
No programs
Analysis
Modality Breakdown
12programs
Small molecule650%
Vaccine650%
Modality classified for 100% of 25 pipeline programs.
Analysis
Trial Status
316
clinical trials
Completed253 · 80%
Unknown status18 · 6%
Recruiting13 · 4%
Terminated11 · 3%
Active, not recruiting9 · 3%
Withdrawn9 · 3%
Other3 · 1%
Clinical Trials
Trial Activity
316 trials
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
Recruiting·—·Phase 3·NCT05726786·232 enrolled
Page 1 of 22
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)